 Tumor Microenvironment
"Tumor Microenvironment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
| Descriptor ID |
D059016
|
| MeSH Number(s) |
G04.366.500
|
| Concept/Terms |
Tumor Microenvironment- Tumor Microenvironment
- Microenvironment, Tumor
- Microenvironments, Tumor
- Tumor Microenvironments
Cancer Microenvironment- Cancer Microenvironment
- Cancer Microenvironments
- Microenvironment, Cancer
- Microenvironments, Cancer
|
Below are MeSH descriptors whose meaning is more general than "Tumor Microenvironment".
Below are MeSH descriptors whose meaning is more specific than "Tumor Microenvironment".
This graph shows the total number of publications written about "Tumor Microenvironment" by people in this website by year, and whether "Tumor Microenvironment" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 2 | 1 | 3 | | 2013 | 2 | 7 | 9 | | 2014 | 1 | 3 | 4 | | 2015 | 7 | 3 | 10 | | 2016 | 6 | 6 | 12 | | 2017 | 2 | 14 | 16 | | 2018 | 7 | 13 | 20 | | 2019 | 15 | 20 | 35 | | 2020 | 14 | 28 | 42 | | 2021 | 7 | 35 | 42 | | 2022 | 2 | 43 | 45 | | 2023 | 2 | 36 | 38 | | 2024 | 15 | 38 | 53 | | 2025 | 8 | 17 | 25 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Microenvironment" by people in Profiles.
-
Nishida-Aoki N, Zhu S, Chan M, Kang Y, Fujita M, Jiang X, McCabe M, Vaz JM, Davidson NE, Ghajar CM, Hansen K, Welm AL, Pillarisetty VG, Gujral TS. Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. Cell Rep Med. 2025 Oct 21; 6(10):102357.
-
Yamada-Hara M, Amaya L, Wang Z, Byun JW, Takahashi N, Sharma S, Chang H, Tanaka A, Zeng L, Malakoutikhah Z, Ganguly S, Vu MC, Levin M, Schwartz D, Heath J, Herdman S, Corr M, Raz E, Bertin S. ROR?t Inhibition Reduces Protumor Inflammation and Decreases Tumor Growth in Experimental Models of Lung Cancer. Cancer Immunol Res. 2025 Sep 02; 13(9):1418-1434.
-
Narikawa Y, Kuramasu A, Hosonuma M, Murayama M, Funayama E, Sasaki A, Baba Y, Toyoda H, Isobe J, Tajima K, Nakashima R, Sasaki A, Maruyama Y, Yamazaki Y, Shida M, Tsurui T, Hirasawa Y, Ariizumi H, Ishiguro T, Suzuki R, Ohkuma R, Kubota Y, Sambe T, Tsuji M, Wada S, Horiike A, Kobayashi S, Tsunoda T, Kobayashi S, Kobayashi H, Oguchi T, Shimane T, Kiuchi Y, Yoshimura K. Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity. Cancer Immunol Immunother. 2025 Aug 19; 74(9):289.
-
Murray AM, Swingle KL, Mitchell MJ. Engineering Nanoparticles for Gynecologic Cancer Therapy. ACS Nano. 2025 Sep 02; 19(34):30758-30785.
-
Yamada H, Yano H, Matsubara E, Zhao S, Shinchi Y, Pan C, Koga T, Fujino K, Fujiwara Y, Ikeda K, Komohara Y, Suzuki M. The expression of PD-1 ligands in the immune microenvironment was altered in TTF-1-negative lung adenocarcinoma. Hum Cell. 2025 Aug 18; 38(5):146.
-
Ghisoni E, Benedetti F, Minasyan A, Desbuisson M, Cunnea P, Grimm AJ, Fahr N, Capt C, Rayroux N, De Carlo F, Gulhan DC, Dagher J, Barras D, Morotti M, Marín-Jiménez JA, Chap BS, Santoro T, Spagnol G, Fleury M, Fortis K, Dorier J, Townsend MK, Tissot S, Rusakiewicz S, Ferreira HJ, Kraemer AI, Bassani-Stenberg M, Swisher EM, Kandalaft LA, Mastroyannis SA, Montone KT, Powell DJ, Banerjee S, Terry KL, Tworoger SS, Pittet MJ, Tanyi JL, Coukos G, Merritt MA, Fotopoulou C, Conejo-Garcia JR, Laniti DD. Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer. Cancer Cell. 2025 Aug 11; 43(8):1568-1586.e10.
-
Sun Y, Fujiwara Y, Torphy RJ, Yee EJ, Guo Y, Sun Z, Hu J, Eck E, Terai T, Schulick RD, Zhu Y. CD93 blockade overcomes sunitinib resistance in pancreatic neuroendocrine tumors. Mol Ther. 2025 Oct 01; 33(10):5017-5027.
-
Rosenbaum SR, Fields KM, Ford HL. Masters of adaptation: How cancer and immune cell plasticity mediates tumor progression. PLoS Biol. 2025 Jul; 23(7):e3003301.
-
Henry CJ, DeGregori J. Modelling the ageing dependence of cancer evolutionary trajectories. Nat Rev Cancer. 2025 Oct; 25(10):757-780.
-
Zahedi S, Riemondy K, Liu T, Griesinger AM, Donson AM, Apfelbaum AA, Fu R, Grandvallet Contreras J, Crespo M, DeSisto J, Groat MM, Bratbak E, Green A, Hankinson TC, Handler M, Vibhakar R, Willard N, Foreman NK, Phang T, Mulcahy Levy J. Multi-pronged analysis of pediatric low-grade glioma and ganglioglioma reveals a unique tumor microenvironment associated with BRAF alterations. Brain Pathol. 2025 Nov; 35(6):e70023.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|